8-K: Sensei Biotherapeutics Reports Positive Preliminary Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics announces favorable initial data from its Phase 1/2 trial of solnerstotug in patients with PD-(L)1 resistant tumors, showing promising clinical activity.

Summary

• Sensei Biotherapeutics announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA, in cancer patients.
• The study enrolled 60 patients, including 40 with hot tumors and 20 with microsatellite stable (MSS) colorectal cancer (CRC).
• Key findings include a 14% Objective Response Rate (ORR) and a 62% Disease Control Rate (DCR) among 21 evaluable PD-(L)1 resistant hot tumor patients.
• One durable complete response was observed in a Merkel Cell Carcinoma (MCC) patient, and two partial responses were seen in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient.
• All PD-(L)1 resistant hot tumor patients with tumor shrinkage remain on the study.
• None of the MSS CRC patients experienced a CR or PR.
• Solnerstotug continues to be well tolerated, with mostly Grade 1 or 2 adverse events.
• Sensei plans to initiate a Phase 2 study in Q1 2026, subject to raising sufficient capital.

Sentiment

Score: 8

Explanation: The document presents positive preliminary clinical data, suggesting potential for solnerstotug in treating PD-(L)1 resistant tumors. The drug appears well-tolerated, and the response rates are encouraging compared to existing options. However, the dependence on raising sufficient capital for Phase 2 introduces some uncertainty.

Positives

• Solnerstotug demonstrates promising clinical activity in PD-(L)1 resistant tumors, with an ORR of 14% and a DCR of 62% in evaluable patients.
• The drug is well-tolerated, with no dose-limiting toxicities and mostly Grade 1 or 2 adverse events.
• There was one durable complete response in a Merkel Cell Carcinoma patient and two partial responses in other patients.
• All PD-(L)1 resistant patients with tumor shrinkage remain on the study, suggesting potential for prolonged benefit.
• Pharmacokinetic data supports once every three week (or greater) dosing.

Negatives

• None of the MSS CRC patients experienced a complete or partial response, consistent with prior checkpoint therapy in this cold tumor type.
• The Phase 2 study is subject to raising sufficient capital, which introduces uncertainty.

Risks

• The Phase 2 study is subject to raising sufficient capital.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There is a risk that prior results observed from preclinical studies and clinical trials will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei's product candidates.

Future Outlook

Sensei plans to initiate a Phase 2 study in Q1 2026, subject to raising sufficient capital, with the trial design and patient selection strategies to be informed by the ongoing dose expansion results.

Management Comments

• Ron Weitzman, M.D., Chief Medical Officer of Sensei Biotherapeutics, stated that checkpoint inhibitor resistance remains a significant challenge for patients with advanced cancer.
• Dr. Weitzman noted that the initial 14% response rate seen with solnerstotug is nearly three times higher than what would typically be expected in this setting.
• Dr. Shiraj Sen, M.D., stated that the observed responses are encouraging given the historically poor prognosis of these patients once they have progressed on checkpoint therapy.

Industry Context

The announcement addresses the significant unmet need in treating patients with tumors resistant to PD-(L)1 inhibitors, a common challenge in oncology. The reported response rate with solnerstotug is notably higher than the estimated 5% likelihood of response to PD-(L)1 rechallenge, suggesting a potential advancement in this difficult-to-treat population.

Comparison to Industry Standards

• The document compares solnerstotug's performance to historical PD-(L)1 rechallenge response rates, which are estimated to be 5% or less.
• Existing immune checkpoint inhibitor (ICI) combination therapies have not been approved in this setting.
• They are either highly toxic, such as CTLA-4+PD-1 in which up to 40% of patients discontinue due to severe immune-related adverse events (irAEs), or offer limited treatment potential, such as LAG-3+PD-1 where the ORR has been 9-12%.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of solnerstotug could provide a new treatment option for cancer patients with PD-(L)1 resistant tumors.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• Sensei plans to initiate a Phase 2 study in Q1 2026, subject to raising sufficient capital.
• Further analyses, including biomarker-based patient selection, are underway to optimize the Phase 2 design.

Key Dates

Keywords

solnerstotug, VISTA, immunotherapy, cancer, PD-(L)1 resistant, clinical trial, Sensei Biotherapeutics